This website is intended for UK healthcare professionals only
Prescribing information can be found here
Why invokana? for T2DM
Invokana Cardiovascular Icon

Cardiovascular Outcomes

Reduce the long-term risk of CV events with Invokana

  • CANVAS showed a 14% relative reduction in risk for MACE among a mix of both primary and secondary prevention patients.
    HR: 0.86 (95% Cl, 0.75-0.97)1 ARR: 4.6 fewer events per 1000 patient-years.
Graph - Death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke

All-cause mortality was the first secondary endpoint in the pre-specified hypothesis testing sequence.
Because analysis of this endpoint failed to show superiority for Invokana, hypothesis testing could not be carried out for the other secondary endpoints.
Simplified statistics (hazard ratios and nominal 95% CIs) are shown for these additional endpoints, but these are not statistically significant.

  • CANVAS also showed a 33% relative reduction in risk of hospitalisation for heart failure among a mix of both primary and secondary prevention patients.
    HR: 0.67 (95% Cl, 0.52-0.87)1 ARR: 3.2 fewer events per 1000 patient-years.
References
  1. Neal B, et al. N Engl J Med. 2017;377(7):644-57